Endo Pharmaceuticals Holdings Inc. was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania. Endo Pharmaceuticals Holdings Inc., a pharmaceutical company, engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain primarily in the United States. Its products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana ER and Opana for the relief of moderate-to-severe pain in patients; Percocet and Percodan tablets; Frova for the treatment of migraine headaches in adults; and Voltaren Gel for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company's products also include Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Sanctura XR to treat OAB symptoms; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer; Delatestryl for the treatment of male hypogonadism; Hydron Implant; and Valstar, a sterile solution of valrubicin for intravesical instillation. Its development stage products include Nebido for treatment of hypogonadisml; PRO 2000, a Phase III clinical stage product for the prevention of infection by HIV and other sexually-transmitted pathogens; octreotide implant, a Phase III clinical stage product for the treatment of acromegaly; and axomadol, a Phase II clinical stage product for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company's generic products include Morphine Sulfate and Endocet, an oxycodone hydrochloride and acetaminophen product. It has strategic alliances with Novartis AG, Hind Healthcare, Penwest Pharmaceuticals Co., and Vernalis Development Limited.

Purely Proteins doesn't mix your ordinary protein shake. Through its proprietary technology, the company purifies human proteins to accelerate biotherapeutic drug discovery and drug screening. Purely Proteins also operates a subscription-based online database of gene and protein information called TargetBASE, which gives chemists and biologists a summary of known and potential protein targets that may help in the discovery of therapies for diabetes, cancer, and Alzheimer's disease. The company conducts its research in conjunction with several business partners, including Abcam Ltd, Asahi Kasei, Cytomyx Limited, and Inhibox Ltd. CEO David Parry-Smith co-founded Purely Proteins in 2002.

Sirtris Pharmaceuticals can help keep you healthy in your golden years. The biopharmaceutical company focuses on developing drugs for treating ailments of aging. Its trial drug for the treatment of Type 2 Diabetes, which is associated with obesity, provides health benefits similar to calorie restriction without a change in diet. Founded in 2004, the company owns or licenses more than 150 patent applications for sirtuins, a class of enzymes. The activation of sirtuins helps reduce weight gain, as well improve glucose levels and insulin sensitivity. Sirtris filed an IPO in 2007, but was then acquired by GlaxoSmithKline (GSK) the following year.

Advanced Vision Research, Inc. company makes TheraTears, a line of over-the-counter eye drops developed to treat dry eye, a condition caused by aging, contact lens wear, sun, or wind. TheraTears are designed to imitate human tears, keeping eyes moist and allowing the surface of the eye to absorb oxygen and other needed nutrients. Other products include a TheraTears version for contact lens-wearers, an Omega-3-infused version to promote eye health, and an eyelid cleanser. Advanced Vision's products are made by Akorn's contract manufacturing unit and are sold through global retail outlets. TheraTears was developed by the late founder and former CEO Jeffrey Gilbard.

Experimental and Applied Sciences (EAS) makes and distributes dietary supplements and weight-management products worldwide. The firm's shakes, nutrition bars, protein drinks, and nutritional supplements -- branded as AdvantEdge, Catapult, EAS, Muscle Armor, and Myoplex -- fuel dieters, body builders, and other athletes. EAS also sells training and exercise videos as well as best-selling book, Body for Life (written by one-time owner Bill Phillips). EAS is part of Abbott Nutrition, a division of leading health care products maker Abbott Laboratories.

Third Wave Technologies is riding the biotech breakers. Using its Invader technology, Third Wave develops molecular diagnostic tests that detect genetic variations associated with a variety of conditions, including cystic fibrosis, cardiovascular risk factors, and infectious disease. Some tests can determine a patient's likely response to certain drugs, making it possible for doctors to avoid prescribing a drug that might cause dangerous side effects. Third Wave company has a strong presence in Japan, where it has a collaboration agreement with genetic researchers at the University of Tokyo. Third Wave Technologies was acquired by Hologic in 2008 for $580 million.

Amgen GmbH speaks the language of biotech geeks, only with a German accent. Amgen GmbH is a German unit of US-based Amgen, the world's largest biotech company. The subsidiary was established in 1989 to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen and Aranesp, for the treatment of anemia in people with chronic kidney disease; Neupogen and Neulasta, to help restore white blood cell counts for cancer patients; and Enbrel, for the treatment of psoriasis and rheumatoid arthritis.

Johnson & Johnson company was founded in 1886 and is based in New Brunswick, New Jersey. Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. Johnson & Johnson has more than 250 operating companies. The Company operates in three segments. The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women’s healthcare fields, as well as nutritional and over-the-counter pharmaceutical products. The Pharmaceutical segment includes products in the therapeutic areas, such as anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers. In July 2009, Johnson & Johnson completed the acquisition of Cougar Biotechnology, Inc. with approximately 95.9% interest in Cougar Biotechnology's outstanding common stock.

ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts. ArQule, Inc. is a clinical-stage biotechnology company engaged in the research and development of cancer therapeutics. The Company’s product is ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase. ARQ 197 is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in Microphthalmia Transcription Factor (MiT) associated tumors, non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma and hepatocellular carcinoma (HCC). The Company has licensed commercial rights to ARQ 197 for human cancer indications to Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) in the United States, Europe, South America and the rest of the world, excluding Japan and certain other Asian countries, where it has licensed commercial rights to Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin).

VIA Pharmaceuticals was founded in 2004 and is headquartered in San Francisco, California. VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the research and development of compounds for the treatment cardiovascular and metabolic diseases. The company is building a pipeline of small-molecule drugs that target inflammation in the blood vessel wall, an underlying cause of atherosclerosis and its complications, including heart attack and stroke. Its principal product, VIA-2291, is in Phase II clinical trials in patients with acute coronary syndrome and patients with stenosis of the carotid artery. The company has agreements with Hoffmann-LaRoche Inc. and Hoffmann-LaRoche Ltd. to develop and commercialize two sets of compounds for the treatment of cardiovascular and metabolic disease.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.